Re: Zenith AGM Corporation Update Slides and Webcast

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith AGM Corporation Update Slides and Webcast

in response to

Re: Zenith AGM Corporation Update Slides and Webcast

BearDownAZ

posted on Nov 20, 2019 11:14AM

Bear, Hopefully the Phase 2a mCRPC trial results are good, but Zenith has yet been able to garnish a large BP partner. I think Zenith needs a large BP partner to help legitimize the epigenetics science to the next level . A BP deal might even help RVX SP for a pending deal on all data related to the BOM trial.